Literature DB >> 26101071

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.

Neil Scolding1, David Barnes2, Sarah Cader3, Jeremy Chataway4, Abhijit Chaudhuri5, Alasdair Coles6, Gavin Giovannoni7, David Miller4, Waqar Rashid8, Klaus Schmierer9, Abdullah Shehu10, Eli Silber11, Carolyn Young12, John Zajicek13.   

Abstract

Entities:  

Keywords:  MULTIPLE SCLEROSIS

Mesh：

Year:  2015        PMID： 26101071     DOI： 10.1136/practneurol-2015-001139

Source DB:  PubMed          Journal:  Pract Neurol        ISSN： 1474-7758


× No keyword cloud information.
  45 in total

Review 1.  Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.

Authors:  Rosa C Lucchetta; Fernanda S Tonin; Helena H L Borba; Letícia P Leonart; Vinicius L Ferreira; Aline F Bonetti; Bruno S Riveros; Jefferson Becker; Roberto Pontarolo; Fernando Fernandez-Llimós; Astrid Wiens
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

Review 2.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  MRI and multiple sclerosis-the evolving role of MRI in the diagnosis and management of MS: a clinician's perspective.

Authors:  H Kearney; A M Cahalane; R P Killeen; C McGuigan
Journal:  Ir J Med Sci       Date:  2017-10-10       Impact factor: 1.568

4.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

Review 5.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

Review 6.  Dimethyl Fumarate: A Review in Relapsing-Remitting MS.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

Review 7.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

8.  The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences.

Authors:  Freya Davies; Fiona Wood; Katherine E Brain; Michelle Edwards; Rhiannon Jones; Rachel Wallbank; Neil P Robertson; Adrian Edwards
Journal:  Int J MS Care       Date:  2016 Sep-Oct

Review 9.  Multiple sclerosis, a treatable disease .

Authors:  Anisha Doshi; Jeremy Chataway
Journal:  Clin Med (Lond)       Date:  2017-12       Impact factor: 2.659

10.  Therapeutic Interferon Interchange in Relapsing Multiple Sclerosis Lowers Health Care and Pharmacy Expenditures with Comparable Safety.

Authors:  Nicole Hahn; Kelsey E Palmer; Shilpa Klocke; Thomas Delate
Journal:  Perm J       Date:  2018-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.